Arrowhead Research

Arrowhead Research is a publicly traded (NASDAQ: ARWR) pharmaceutical company that is a component of the NASDAQ Biotechnology Index.[1] As of 2016, it has no marketed products. Products in development are RNA therapeutics acting through RNA interference mechanisms of action.[2] The company focuses on treatments for Hepatitis B,[2][3][4] and Carcinomare.[1][5] The company has six products in its pipeline, in various stages of clinical development.[6]

Product Indication Development phase
ARC-520 Hepatitis B Phase II
ARC-521 Hepatitis B Pre-Clinical
ARC-AAT Alpha-1 Antirypsin Deficiency Phase I
ARC-F12 Thrombosis Pre-Clinical
ARC-HIF2 Carcinomare Pre-Clinical
ARC-LPA Cardiovascular Disease Pre-Clinical

In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio and assets from Novartis.[7]

References

  1. 1 2 "Arrowhead Added to NASDAQ Biotechnology Index" (Press release). Arrowhead Research. 14 December 2015. Archived from the original on 4 March 2016. Retrieved 4 January 2016 – via FOX 29 WFXL website.
  2. 1 2 "Arrowhead's ARC-520 Leads to Consistent Immune Reactivation in Chimpanzees with Chronic Hepatitis B Infection" (Press release). Arrowhead Research. 7 December 2015. Archived from the original on 5 March 2016. Retrieved 4 January 2016 – via Reuters.
  3. ↑ Calia, Michael (12 January 2015). "FDA Informs Arrowhead of Partial Clinical Hold for Hepatitis B Drug". The Wall Street Journal. Retrieved 4 January 2016.(subscription required)
  4. ↑ Haussecker, Dirk (8 November 2013). "Gilead Lead Chronic HepB Candidate GS-9620 Conceived as a More Patient-Friendly Interferon" (blog post). HEPBBLOG (Reprint of posting on RNAi Therapeutics Blog). Hepatitis B Foundation. Retrieved 8 June 2016. GS-9620 is therefore an example of the typical incrementalist Big Pharma value creation strategy. By contrast, if successful, an HBsAg knockdown approach such as with Arrowhead’s ARC520 would bring to healthcare providers and patients an entirely new, desperately needed treatment option as the field has become stuck with interferons and RT inhibitors for years.
  5. ↑ "Arrowhead Nominates ARC-HIF2 As First RNAi Therapeutic Candidate Using Extrahepatic DPC™ Delivery System" (Press release). Arrowhead Research. 11 September 2015. Retrieved 4 January 2016 – via Yahoo! Finance.
  6. ↑ "Arrowhead Research Corporation | Programs Overview". Arrowhead Research. Retrieved 4 January 2016.
  7. ↑ Staff (1 April 2015). "Novartis Sells RNAi R&D Portfolio to Arrowhead in $35M Agreement". News: Industry Watch. Genetic Engineering & Biotechnology News (Paper). 35 (7): 10.
This article is issued from Wikipedia - version of the 11/16/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.